Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Telsar Pharma Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT01612039
A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- Telsar Pharma Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01320332
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath